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                                  INTRODUCTION
Tracheal intubation as well as extubation often provoke significant cardiovascular 
changes with marked increase in heart rate and blood pressure1-3.  These hemodynamic changes 
during extubation are probably of little consequence in healthy individuals but may be more 
severe and more dangerous in hypertensive patients4.  Hemodynamic changes during 
extubation and emergence from anaesthesia may cause dangerous increase in myocardial 
oxygen demand in patients with coronary artery disease and in those with risk factors for 
CAD4,5. Several drugs like lignocaine, esmolol, alfentanil, fentanyl, prostaglandin E1 and 
diltiazem are used to attenuate the cardiovascular responses to tracheal extubation in 
normotensive patients6-10.
Diltiazem a calcium channel blocker has been used extensively to maintain perioperative 
hemodynamic  stability11,12.   This  drug  is  effective  in  blunting  the  hemodynamic  changes 
associated with laryngoscopy and tracheal intubation13.  The exact mechanism whereby tracheal 
intubation and extubation cause hemodynamic changes may be different and remain as yet to 
be elucidated.
Tracheal  intubation  produces  a  profound  but  short  uniform  stimulation  in  the 
anaesthetized  patient.  But  during  tracheal  extubation  stimulation  which  affects  the 
hemodynamic changes is multifactorial; e.g., pain of the wound, emergence from anaesthesia 
and tracheal irritation.  Even if a drug is used effectively to control cardiovascular changes 
during tracheal intubation, its dose and timing of dosing most probably are different during 
extubation.
Because the pharmacological mechanism for the control of the hemodynamic changes 
during extubation is thought to differ between diltiazem and lignocaine, combining these two 
drugs  may  be  more  effective  than  giving  each  drug  alone  for  attenuating  cardiovascular 
responses.  The present study was undertaken to compare the efficacy of diltiazem along with 
lignocaine  with  each  drug  given  alone  in  suppressing  the  hemodynamic  changes  during 
extubation in normotensive patients.
After getting approval from the hospital ethical committee, the study was carried out in 
the  Department  of  Anaesthesiology,  Madras  Medical  College  and  Government  General 
Hospital, Chennai.   
AIM OF THE STUDY
The aim of the study is to evaluate the efficacy of combination of diltiazem with 
lignocaine in suppressing the hemodynamic changes during tracheal extubation and to 
compare the effects with these drugs given individually.
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TRACHEAL EXTUBATION
Extubation of the trachea is the Cinderella of anaesthetic practice.  Although it 
seems that  there are more problems associated with extubation than intubation the 
world wide incidence is not known.  A recent review4 concluded that extubation is 
associated with much short-term morbidity and occasionally mortality.
The common problems associated with tracheal extubation are 
1. Physiological responses to tracheal extubation:
Dyson and colleagues7 recorded increases of 20% or more in both heart rates 
and systolic arterial pressures in about 70% of normal patients who were extubated 
under standard conditions. This response was increased in hypertensive, cardiac and 
neuro  surgical  patients.   The  response  in  pre-eclamptic  patients  can  also  be  very 
severe, culminating in pulmonary edema and death. 
2. Trauma:
11
Trauma to any of the structures forming the upper and lower airway is possible 
during tracheal extubation.
3. Airway obstruction:
Airway obstruction following tracheal extubation is commonly due to –
A : Laryngospasm
B : Laryngeal oedema
C : Vocal cord paralysis
D : Tracheal collapse.
A:  Laryngospasm:  
Defined as an occlusion of the glottis by the action of intrinsic laryngeal 
muscles.  Laryngospasm is the most common cause of upper airway obstruction after 
tracheal extubation. It is particularly frequent in children after upper airway surgery 
and is most likely to occur after tracheal extubation of a patient in lighter planes of 
anaesthesia. The main treatment is administration of 100% oxygen with continuous 
positive airway pressure. Intravenous doxapram, lignocaine, diazepam and 
suxamethonium chloride followed by reintubation and ventilation have all been used 
in the treatment of laryngospasm. 
B:Laryngeal edema:
 It is an important cause of upper airway obstruction after extubation in children 
particularly neonates and infants.  Oedema may be localized to supraglottic, subglottic 
12
or retro arythenoid regions.  In a study by Koka et al factors that showed a positive 
correlation with the development of laryngeal edema in children included the use of a 
tight fitting endotracheal tube, trauma during intubation and duration of intubation. 
The presence of upper airway infection was not a significant contributory factor.14
C:Vocal cord paralysis:
Rare but important cause of airway obstruction.  It results from trauma to the 
vagus nerve or its branches and is described after surgical procedures involving the 
head and neck, the thyroid gland or thoracic cavity.  It has been suggested that tracheal 
intubation  itself  may  result  in  nerve  damage  leading  onto  vocal  cord  palsy.  The 
recurrent laryngeal nerve after leaving the thorax travel in the tracheo- oesophageal 
groove towards the larynx where they divide into anterior and posterior branches.  The 
anterior branch has been found to be susceptible to compression by the tracheal tube 
cuff where they lie beneath the muscle and immediately medial to the lamina of the 
thyroid cartilage. 
D:Tracheal Collapse:
May result  from prolonged  compression  by  an  expanding  goitre  or  tumour 
particularly within the confines of the thoracic inlet.  Tracheal collapse occurs after 
extubation  and  requires  emergency  reintubation.   The  subsequent  options  include 
surgical  resection  of  the  affected  segment  or  airway  diversion  below the  affected 
trachea through a tracheostomy.
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4. Pulmonary edema associated with upper airway obstruction:
This usually occurs within minutes of development of upper airway obstruction 
or after relief of obstruction.   The pathogenesis  is  multifactorial,  but the markedly 
negative  intrathoracic  pressure  generated  during  an  episode  of  acute  upper  airway 
obstruction  is  the  dominant  mechanism.   Resolution  occurs  spontaneously  over  a 
period  of  hours.  Essentials  of  management  include  maintenance  of  airway, 
administration of oxygen and positive pressure ventilation if required.
5. Pulmonary aspiration of gastric contents:
Can occur if the patients are not fully conscious and able to protect their airway.
6. Post operative sore throat:
Cuffs with a longer cuff–trachea interface appear to cause a higher incidence of 
sore throat 15. The incidence of sore throat may also be related to intracuff pressures. 
One study demonstrated that tube size is related to the incidence and severity of sore 
throat in both sexes16. 
7. Difficulty in extubation:
This could be due to inability to deflate the tracheal cuff, a large cuff catching 
onto the vocal cords or the endotracheal tube getting transfixed by a suture or a wire to 
an adjacent structure.
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PHYSIOLOGICAL RESPONSES TO EXTUBATION
CARDIOVASCULAR EFFECTS:
Many investigators  have documented that  tracheal  extubation causes modest 
(10-30%) and transient increases in blood pressure and heart rate lasting 5-15 min17-19. 
Coriat  et  al  demonstrated  that  patients  with  coronary  artery  disease  experience 
significant  decrease  in  ejection  fraction  (from  55%   + 7%  to  45%  + 7%)  after 
extubation20.  The changes in ejection fraction occurred in the absence of ECG signs of 
myocardial ischemia. Wellwood et al reported that patients with a cardiac index of less 
than 3.0 L/min/m2 did demonstrate an ischemic response to stress of postoperative 
tracheal extubation after myocardial re vascularisation21.  These patients experienced 
decrease in myocardial lactate extraction, LV compliance and cardiac performance. 
Tracheal  extubation  after  cesarean  section  in  parturients  with  gestational 
hypertension can cause significant increase of 45 and 20mm Hg in mean arterial and 
pulmonary artery pressures respectively.  It was concluded that tracheal extubation and 
related  hemodynamics  increased  the  risk  of  cerebral  hemorrhage  and  pulmonary 
edema in them 22.
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In hypertensive patients, emergence from anaesthesia and tracheal extubation is 
associated with significant increase in heart rate and blood pressure. Fuji et all studied 
the cardiovascular responses to tracheal extubation or LMA removal in normotensive 
and hypertensive patients23.  They concluded that hemodynamic variables immediately 
following  extubation  or  LMA  removal  from  baseline  values  were  greater  in 
hypertensive  patients  than  in  normotensives.  Hypertensive  patients  thus  exhibit  an 
exaggerated response to tracheal extubation when compared to normotensive patients. 
Coughing  often  occurs  during  tracheal  extubation.   Coughing  can  lead  to 
increase in intrathoracic pressure, which can interfere with venous return to the heart. 
In a study by Kern et al  24 coughing significantly increased systolic pressure (from 
137+ 25 to 176  + 30 mm Hg), diastolic pressure (71+ 10 to 84  + 18 mm Hg) and 
arterial pulse pressure (from 65 + 27 to 92 + 35 mm Hg) without changing heart rate. 
Mean coronary  flow velocity  decreased (from 17  + 10 to  14  + 12 cm/s)  in  these 
patients.
In  summary significant hemodynamic stimulation to  varying degrees can be 
transiently  produced  by  tracheal  extubation.   Although  these  changes  are  usually 
inconsequential  patients  at  particular  risk  may  be  adversely  affected  by  tracheal 
extubation.  Thus the potential for deletrious hemodyamic events to follow extubation 
should not be ignored.
Neurologic effects of extubation:
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Laryngoscopy  and  intubation  increases  intracranial  pressure  the  greatest 
increase being elicited in patients with decreased intracranial compliance25.  However 
the effects of tracheal extubation on ICP have not been investigated. Although it is 
likely that extubation causes transient increases in ICP, the existence of such effects 
must be extrapolated from other data. 
Donegan  and  Bedford26 reported  that  ICP  increased  by  12  + 5  mm Hg  in 
comatose  patients  whose  tracheas  were  suctioned.   White  et  al27 also  found  ICP 
increased  from  15  + 1  to  22  + 3  mm  Hg  after  endotracheal  suctioning  in  fully 
resuscitated comatose intensive care unit patients.  The ICP increases lasted for less 
than 3 min after suctioning.  Both authors hypothesized that coughing associated with 
endotracheal  suctioning  causes  ICP  to  rise  by  increasing  intrathoracic  pressure, 
cerebral venous pressure and cerebral blood volume.
Increases  in  arterial  blood pressure  often  result  from tracheal  extubation  as 
mentioned  above  and  arterial  hypertension  can  also  lead  to  or  be  associated  with 
intracranial  hemorrhage  or  increase  in  ICP28.  Possibly,  associated  hemodynamic 
changes,  during  and  after  extubation  can  also  negatively  impact  patients  with 
intracranial pathology.
In  summary  coughing,  bucking  and  arterial  hypertension  during  tracheal 
extubation  can  all  be  detrimental  especially  in  patients  with  existing  intracranial 
pathology.
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Hormonal effects of extubation;
Recognition that  a  significant and potentially  deleterious stress  response can 
result  from the induction of anaesthesia,  tracheal intubation and surgery has led to 
numerous  documentations  of  this  phenomenon.   On the  other  hand,  the  endocrine 
response to tracheal extubation has received little attention. Lowrie et al19 evaluated 
the impact of tracheal extubation on changes in plasma concentrations of epinephrine 
and norepinephrine in patients undergoing major elective surgery.  Epinephrine levels 
were  significantly  increased  only  5  min  after  extubation.   Norepinephrine  levels 
remained unchanged. 
Adams  et  al29 performed  an  investigation  in  which  40  patients,  undergoing 
herniorrhaphy  or  cholecystectomy,  were  anaesthetized  with  either  isoflurane  or 
halothane  and  extubated  at  0.5  MAC depth  of  anaesthesia  or  awake.   Significant 
increase in plasma epinephrine levels occurred in all patients.  Norepinephrine levels 
also increased in all patients except those extubated awake after halothane anaesthesia. 
Although antidiuretic hormone levels increased in all patients after extubation, neither 
adrenocorticotrophic hormone nor cortisol levels did.  These investigations indicate 
that an endocrine response to tracheal extubation can occur.
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PHARMACOLOGY OF LIGNOCAINE
Lignocaine  is  an  amide  local  anaesthetic  with  antiarrhythmic  properties. 
Lofgren first noted that all local anaesthetics have a hydrophilic portion (secondary or 
tertiary amine) and a lipophilic portion (aromatic residue) separated by an intermediate 
chain.  Linkage to the aromatic residue has provided a means for classification of local 
anaesthetics.  Local anaesthetics with an ester linkage between the aromatic residue 
and  intermediate  chain  are  AMINOESTERS (procaine,  chloroprocaine  and 
tetracaine)  and  those  with  an  amide  linkage  between  the  aromatic  residue  and 
intermediate chain are AMINOAMIDES (lignocaine, bupivacaine, mepivacaine etc,)
It belongs to the class Ib of the Vaughan Williams classification of 
antiarrhytmic drugs. Lignocaine blocks the fast sodium channels in the cell membranes 
of myocardial cells and reduces the rate of rise of the action potential in the His 
purkinje system and the ventricular musculature.  The duration of the action potential 
and effective refractory period are reduced.  The sinoatrial node and atrio-ventricular 
node are not affected by therapeutic concentrations of lignocaine.
Pharmacokinetics:
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The pharmacokinteics of lignocaine is well described by a two compartment 
model following a single intravenous dose.  Its distribution half life (t ½ ∝) is around 8 
minutes and its elimination half life (t ½ β) is around 90 to 110 minutes.  Lignocaine is 
metabolized in the liver to monoethylglycinexylidine (MEGX) and glycinexylidine 
(GX) which are then excreted by the kidney.  As lignocaine is rapidly cleared by the 
liver its plasma steady state concentration depends on the hepatic blood flow.  Thus in 
conditions where hepatic blood flow is reduced as in congestive cardiac failure or in 
the presence of hepatic disease the dosage of lignocaine should be reduced. Lignocaine 
has a molecular weight of 234. Its protein binding is between 60-75% Therapeutic 
plasma concentrations required to produce an antiarrhytmic effect is around 1.5μg/ml. 
Convulsion occurs at a plasma concentration of around 10 μg/ml.
Indications:
1. Intravenous  lignocaine  is  the  drug  of  choice  for  management  of  ventricular 
arrhytmias like ventricular premature contractions.
2. Intravenous  lignocaine  is  used  during  anaesthesia  to  prevent  the  pressor 
response to laryngoscopy and intubation. 
3. Lignocaine  is  used  as  a  local  anaesthetic  for  topical  infiltration  and  other 
regional anaesthetic procedures.
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It is available as 1%, 2%, 4% and 10% solutions.  A 5% solution with 7.5% 
dextrose is available for subarachnoid block.  The preparations for intravenous use do 
not  contain preservatives.  Usual  dose  for  intravenous administration is  1-1.5mg/kg 
body  weight  followed  by  an  infusion  at  a  rate  of  1-4  mg/min  if  required.   For 
infiltration lignocaine can be used up to a maximum dose of 3mg/kg body weight 
without adrenaline and 7mg/Kg body weight with adrenaline. 
Contraindications:
1. Hypersensitivity to lignocaine.
2. Hypersensitivity to other amide local anaesthetics.
Precautions
1. Patients with hepatic or renal dysfunction:
Lignocaine is mainly metabolised in the liver and the metabolites are execreted 
by the kidney.  Caution should be observed while administering lignocaine to patients 
with these disorders especially as infusion as it may lead on to an accumulation of 
metabolites potentiating toxicity.
2. When high doses are used in patients with impaired myocardial function it can 
potentiate the negative inotropic effect and cause clinical hypotension. 
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3. Serum potassium levels should be normalized prior to starting an infusion of 
lignocaine.
Toxicity:
Toxicity of local anaesthetics chiefly involves the central nervous system and 
cardiovascular system.  The earliest symptoms in an awake patient include circumoral 
paraesthesias and numbness, which then proceeds onto tinnitus, nystagmus and 
dizziness.  Further increase in plasma concentration can lead onto CNS excitation 
restlessness and tremors leading onto convulsions.  Local anaesthetics cause peripheral 
vasodilation and myocardial depression. At toxic doses the combined effects of 
peripheral vasodilation, negative inotropic effect and a depressant action on cardiac 
conduction can lead onto circulatory collapse and cardiac arrest.
The ratio of the dosage or blood levels required to produce irreversible 
cardiovascular collapse to the dosage or blood levels required to elicit convulsions is 
the CC/CNS ratio.  The CC/CNS ratio for lignocaine in adult non-pregnant sheep is 7 
indicating that 7 times as much drug is needed to produce irreversible cardiovascular 
collapse as is required to produce convulsions. Hence central nervous system 
symptoms provide a warning in an awake patient of high plasma levels and impending 
cardio vascular collapse
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Management of Toxicity:
1. Administer oxygen, intubate if necessary.  
2. Seizures are managed by intravenous benzodiazepines or thiopentone sodium.
3. Cardio vascular depression is managed by intravenous fluid administration and 
vasopressors.  Prolonged inotropic support may be required.  
4. Hypoxia  and  acidosis  worsen  cardiovascular  collapse  and  should  be 
aggressively managed.
CALCIUM CHANNEL BLOCKERS
Drugs that are classified as calcium channel blockers act selectively on 
specialized membrane channels inhibiting the inward movement of calcium ions into 
cardiac and smooth muscle cells.  In contrast to skeletal muscle, which contains 
adequate stores of calcium ions, cardiac and vascular smooth muscle are dependent on 
extra cellular calcium for their contractile function.
The  entry  of  calcium  ions  into  the  cells  occur  through  specific  gates  or 
membrane  channels  that  can  be  opened or  closed.   Some of  them are  opened by 
stimulation of nearby adrenergic receptors (receptor operated channels) while others 
are  opened  by  depolarization  of  the  cell  membrane  (Voltage  activated  channels). 
These calcium ion conductance channels are sometimes referred to as 'Slow Channels' 
in contrast  to the 'Fast  Channels'  that  conduct sodium.  The various voltage gated 
calcium ion channels include.
Voltage sensitive calcium channels
S.No.
L - Type
(Long lasting 
current)
T – Type
(Transient 
current)
N – Type
(Neuronal)
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01. Conductance 25 ps. 8 ps. 12-20ps.
02. Activation threshold High Low High
03. Inactivation rate Slow Fast Medium
S.No.
L - Type
(Long lasting 
current)
T – Type
(Transient 
current)
N – Type
(Neuronal)
04. Location and function
Excitation – 
contraction – coupling 
in cardiac and smooth 
muscle . SA, AV mode 
– conductivity – 
Endocrine cells – 
hormone release – 
neurons – transmitter 
release.
SAnode – 
pacemaker activity. 
T current and 
repetitive spikes in 
thalamic and other 
neurons. Endocrine 
cells – hormone 
release. Certain 
arteries 
constriction.
Only on neurons in 
CNS, sympathetic 
& myentric 
plexuses – 
transmitter  release.
05. Blocker Nifedipine, diltiazem, verapamil.
Mebefradil, 
flumarizine, 
ethosuximide.
ω-conotoxin.
Most  of  the  commercially  available  calcium  channel  blocking  agents 
exclusively block the L– Channels.
Role of calcium ions in cardiac and smooth muscle cells.
The cardiac action potential can be divided into five phases.
Phase O: Rapid Depolarisation: This is due to the opening of fast sodium 
channels and a rapid influx of sodium ions. 
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Phase 1 : Early Repolarisation: Here the sodium channels close but the 
membrane conductance for calcium and potassium ions increase.  The 
overall effect is a small change of the membrane potential towards the 
resting membrane potential.
Phase 2: Plateau : This is due to an increase in membrane conductance to 
calcium ions. 
Phase 3: Rapid repolarisation:  There is reduction in the inward movement of 
calcium ions and potassium ion efflux. 
Phase 4: In  non  –  pacemaker  cells  this  phase  is  characterized  by  a  constant 
membrane  potential.   In  pacemaker  cells  there  is  a  slow  diastolic 
depolarization which brings the membrane potential near the threshold 
potential. 
Thus calcium ions are responsible for the Phase 1 and Phase 2 of the action 
potential in cardiac cells. But in specialized cells like pace maker cells and conducting 
tissue Phase O occurs as a result of slow calcium influx.
In smooth muscle cells:
The inward flux of calcium ions produces additional release of calcium from the 
intracellular storage sites.  This calcium then binds to calmodulin, a calcium binding 
protein.  The calcium-calmodulin complex activates myosin light chain kinase, which 
phosphorylates myosin.  This results in actin-myosin interaction leading onto muscle 
contraction.
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In cardiac muscle:
Calcium ions bind on to the protein troponin.  This results in the release of 
inhibition of troponin on the interaction between action and myosin.  Actin myosin 
interaction leads onto muscle contraction. 
Thus  calcium ions  play  an  important  role  in  coupling  the  depolarization  of 
myocardial  and  smooth  muscle  cells  to  muscle  contraction.  Excitation  contraction 
coupling.
Commercially available calcium channel blockers can be classified on the basis 
of their chemical structure into 
1. PHENYLALKYLAMINES - Verapamil
2. BENZOTHIAZEPINES - Diltiazem
3. DIHYDROPYRIDINES - Nifedipine.
All voltage sensitive calcium channels are membrane spanning funnel shaped 
glycoproteins that function as ion selective valves.  They are composed of major  α1 
subunit which encloses the ion channel and other modulatory subunits like α2, β, δ.  In 
L-type  Ca2+ channels  each  subunit  exists  in  multiple  isoforms,  which  may be  site 
specific.
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            Skeletal muscle L – Channels -αIS, α2/δa, β1 -γ 
Cardiac muscle L – Channels -  αIca, α2/δc, β2 
Smooth muscle L – Channels -  αIcb, α2/δ, β3
All these drugs prevent calcium ion entry into cardiac and smooth muscle cells 
by blocking the  α1 subunit of L type voltage gated calcium channels. They differ in 
their  tissue  selectivity  and  mechanism  of  blockade.   Dihydropyridines  are  more 
selective  for  arteriolar  beds  while  phenylalkylamines  and  benzothiazepines  are 
selective for the atrioventricular node.
Common indications for calcium channel blockers :
1. Angina Pectoris: Calcium  channel  blockers  have  been  used  in  the 
management of stable and vasospastic angina.  The mechanisms by which they are 
thought to play a beneficial effect in angina include. 
a) increased  myocardial  oxygen supply  due  to  coronary  artery  dilatation 
and an increase in coronary blood flow.
b) decreased  myocardial  oxygen  demand  due  to  decrease  in  peripheral 
vascular resistance, myocardial contractility and heart rate.
2. Hypertension: Calcium  channel  blockers  by  virtue  of  their  peripheral 
vasodilation have been used in the management of systemic arterial hypertension.
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3. Supraventricular arrhytmias: Verapamil and Diltiazem have been used for 
the  management  of  supraventricular  arrhytmias.   Both  these  drugs  prolong  the 
refractory period of the atrio-ventricular node.  This is one of the main mechanism by 
which nodal supraventricular arrhytmias are abolished and the rate in atrial flutter and 
fibrillation controlled.  These drugs have been used in the conversion of paroxysmal 
supraventricular  tachycardia  to  sinus  rhythm  as  well  as  controlling  the  rapid 
ventricular rate in atrial fibrillation.
Other indications of calcium channel blockers:
1. Cerebral vasospasm accompanying subarachnoid hemorrhage:
Nimodipine which selectively dilates the cerebral arteries has been widely used 
in the management of cerebral vasospasm.
2. Cerebral protection after global ischemia:
Calcium channel blockers by virtue of blocking the calcium ion influx has been 
studied for cerebral protection following induced or accidental cardiac arrest.
3. Hypertrophic cardiomyopathy.
4. Adjunct to cold cardioplegia.
5. Primary pulmonary hypertension.
6. During harvest of radial artery grafts in coronary artery bypass surgery:
Dilitiazem has been used as an infusion to prevent vasospasm of radial 
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artery  grafts  intraoperatively  and  during  the  immediate  post  operative  period  in 
patients undergoing coronary artery bypass surgeries.
7. Preterm labour: Oral nifedipine has been used in preterm labour as a tocolytic.
8. Calcium  channel  blockers  have  been  used  in  vasospastic  conditions  like 
Raynand's disease.
9. Non-specific calcium channel blockers like cinnarizine have been used in the 
management of migraine.
Comparative properties of calcium channel blockers
 
S.No. Verapamil Nifedipine Diltiazem
01.
Channel blocking 
potency
++ +++ +
02.
Frequency 
dependence of 
channel blockade.
++ - +
03.
Channel recovery 
rate.
Much delayed No effect Less delayed
04.
Cardiac effects: 
heart rate
 ↓ ↑ ↓
A-V conduction 
velocity.
 ↓ ↓ -  ↓
Contractility -,  ↓ ↑ ↓
Output -,  ↓ ↑ -, ↑
05.
Vascular smooth 
muscle relaxation
++ +++ +
06. Clinical use in Angina 
Arrhythmia 
Angina 
Hypertension 
Angina, 
Hypertension 
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Hypertension
Congestive heart 
failure
Arrhythmia.
Diltiazem 
Diltiazem  hydrochloride  predominantly  blocks  the  calcium  channels  in  the 
atrioventricular node. 
The pharmacological effects include – 
- Decrease in myocardial contractility
- Decrease in heart rate.
- Decrease in rate of conduction through the AV node.
- Dilation  of  vascular  smooth  muscle  resulting  in  decreased  blood 
pressure. 
The effects of diltiazem on the sinoatrial node, atrioventricular node and its 
vasodilating properties appear to be intermediate between verapamil and nifedipine.
Pharmacokinetics:
Following  oral  administration  over  90%  is  absorbed  but  bioavailability  is 
around 40-45% due to first pass hepatic metabolism.  Onset of action is between 15-30 
min with a peak at 1-2 hours. Elimination half-life is 4-6 hours. Protein binding is 
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around  80-85%.   The  therapeutic  plasma  concentration  is  around  100-250  ng/ml. 
Diltiazem is metabolized in the liver by acetylation.  Unlike verapamil and nifedipine 
only 35% is excreted through the kidneys, the remaining being eliminated by the liver. 
It is available as 30mg, 60 mg and 90mg tablets and 120 mg sustained release tablets. 
Patients are started on 30 mg four times daily and increased to a maximum of 180 – 
240 mg per day. 
The intravenous preparation is a clear, colourless solution with pH between 2.7- 
4.1.  Following  a  single  intravenous  injection  it  appears  to  obey  linear 
pharmacokinetics over a dose range of 10.5 – 21 mg.  The onset of action after a single 
intravenous  bolus  dose  is  between  30  sec.  and  1min.  with  the  peak  effect  at  2-5 
minutes.  Its apparent volume of distribution is around 305 litres. The high volume of 
distribution is due to its lipid solubility.
It  is  available  as  5ml  vials  with  each  vial  containing  25mg  of  diltiazem 
hydrochloride (5mg/ml).  The intravenous dose is 75-150 μg/Kg.
Contraindications
1. Patients with sinus bradycardia, sick sinus syndrome, second or third degree 
AV block.
2. Patients with atrial fibrillation or atrial flutter associated with an accessory 
bypass tract such as in WPW syndrome.
3. Patients receiving intravenous beta adrenergic blockers should not be 
administered intravenous diltiazem concomitantly.
4. As there are no well-controlled studies in pregnant women, diltiazem should be 
used during pregnancy only if the potential benefit to the mother justifies the 
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potential risk to the fetus.
5. Patients with known hypersensitivity to the drug.
Adverse Effects
1. Hypotension:  Hypotension  can  occur  which  usually  responds  to  intravenous 
normal saline or placing the patient in Trendelenberg position. 
2. Bradycardia, junctional rhythm and high degree AV block can occur especially 
in patients with pre-existing nodal disease.
3. Other side effects include headache, dizziness, ankle edema and constipation 
particularly with the oral medication.
4. Elevation of liver enzymes has also been reported. 
ANAESTHETIC IMPLICATIONS
i) Interaction with Volatile anaesthetics:
Calcium channel blockers are vasodilators and myocardial  depressants.   The 
negative inotropic effects, depressant effects on sinoatrial node function and peripheral 
vasodilating effect of these drugs and those of volatile anaesthetics are similar and 
there is evidence that volatile anaesthetics have blocking effects on calcium channels. 
Enflurane when combined with calcium channel blockers produces more myocardial 
depression than halothane. 
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ii) Neuromuscular blocking drugs:
Calcium  channel  blockers  potentiate  the  effects  of  depolarizing  and  non-
depolarizing  neuromuscular  blocking  drugs.   This  potentiation  resembles  that 
produced  by  mycin  antibiotics.   The  postulated  mechanisms  include  presynaptic 
alterations,  reducing  calcium concentration,  blocking  of  sodium channels  etc.  The 
local  anaesthetic  effect  of  verapamil  may  also  contribute  to  potentiation  of 
neuromuscular blocking drugs. 
iii) Potassium containing solution:
Calcium  channel  blockers  slow  the  inward  movement  of  potassium  ions. 
Hyperkalemia can occur in patients being treated with calcium channel blockers after 
much smaller amounts of exogenous potassium infusion as associated with use of KCl 
to treat hypokalemia or administration of stored whole blood. 
iv) Dantrolene:
The  administration  of  dantrolene  in  the  presence  of  verapamil  or  diltiazem 
results  in  hyperkalemia  and  cardiovascular  collapse.   Whenever  calcium  channel 
blockers and dantrolene are to be administered concurrently invasive hemodynamic 
monitoring  and  frequent  measurement  of  plasma  potassium  concentration  are 
recommended. 
v) Digoxin:
Calcium channel blockers may increase the plasma concentration of digoxin 
presumably by decreasing its plasma clearance. 
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vi) Platelet function:
Calcium  channel  blockers  may  interfere  with  calcium  medicated  platelet 
functions.
REVIEW OF LITERATURE
REID AND BRUCE (1940) postulated that reflex circulatory responses to 
laryngeal instrumentation were mediated through the vagus nerve and they named it as 
"Vaso Vagal Reflex".
WYCOFF.C.C.(1960)30 in  his  study  stated  that  topical  anaesthesia  of  the 
pharynx along with  superior  laryngeal  nerve  blocks  reduced the  increase  in  mean 
arterial pressure after intubation. 
STEINHAUS  &  GASKIN  (1963)31 found  that  intravenous  lignocaine 
suppressed the cough reflex. 
MASON & ECKANKOFF (1971) proved that the hypertensive response in 
patients can be significantly decreased by simple lignocaine spray. 
PRYS ROBERTS et al (1971) found that the increase in heart rate and blood 
pressure are much more exaggerated in hypertensive patients. 
DENLIGNER.J.K.  and  ELLISON.N.E.  (1974)33 have  used  intratracheal 
lignocaine spray which causes a 50% reduction in the hypertensive response. 
           BIDWAI AV & STANLEY TH (1978)17 demonstrated  that  tracheal 
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administration of 1.5cc of 4% Lignocaine 3 to 5 min prior & 1cc of 4% lignocaine at 
extubation  prevented  increase  in  heart  rate  and  blood  pressure  during  tracheal 
extubation.
BIDWAI  AV  &  BIDWAI  VA  (1979)6 demonstrated  that  intravenous 
administration of lignocaine 2mg/kg body weight 2min prior to extubation prevented 
increase in heart rate and blood pressure. 
DYSON A(1990)7 in  his  study  found  that  esmolol  when  given  as  a  single 
intravenous bolus dose of 1.5mg/kg body weight 2 to 5 minutes before extubation 
attenuates the cardiovascular responses to tracheal extubation.
MUZZI  et  al(1990)48 in  his  study  compared  labetolol  and  esmolol  in  the 
control  of  hypertension  after  intracranial  surgery  and  found  that  the  incidence  of 
bradycardia  in  the  immediate  postoperative  period  was  significantly  higher  with 
labetolol.
           FUHRMAN et al (1992)8 compared the efficacy of alfentanil a short acting 
opioid  with  esmolol  a  short  acting  beta  adrenergic  blocker  in  attenuating  the 
hemodynamic changes during extubation.  They found that esmolol was superior to 
alfentanil  in  attenuating  the  hemodynamic  changes  when  given  as  bolus  dose  at 
discontinuation of anaesthesia.
NISHINA  et  al  (1995)9 studied  the  effects  of  fentanyl  in  blunting  the 
hemodynamic responses to tracheal extubation.  They studied 60 females undergoing 
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elective  gynaecological  surgeries  and  who  randomly  received  saline,  1μg/kg  body 
weight fentanyl, 2μg/kg body weight fentanyl intravenously at the time of peritoneal 
closure.  It was demonstrated that cardiovascular changes during tracheal extubation 
were  attenuated  by  a  single  dose  of  fentanyl  (2µg/kg).   But  such  techniques  can 
produce depression of respiratory and cardiovascular systems and may also result in 
difficulty in management of airway. 
 NISHINA et al (1995)50 studied the attenuation of the cardiovascular changes 
during tracheal extubation with diltiazem (0.1mg/kg and 0.2 mg/kg body weight) and 
compared  it  with  lignocaine  1mg/kg  body  weight.   They  found  that  a  bolus  of 
diltiazem 0.2mg/kg body weight had the greatest inhibitory effect while the extent of 
attenuation with diltiazem 0.1mg/kg was similar to lignocaine 1mg/kg body weight.
NISHINA K and MIKAWA K(1996)10 in their study found that prostaglandin 
E1  in a dose of 0.1μg/kg/min infusion started at the end of surgery and continued until 
5 minutes after extubation attenuated the hypertensive response to tracheal extubation 
but failed to blunt the tachycardia associated with tracheal extubation. 
MIKAWA et al(1996)49 studied the effect of intravenous verapamil (0.05mg/kg 
and 0.1 mg/kg) body weight on the cardiovascular changes during tracheal extubation 
and compared the same with diltiazem (0.2mg/kg body weight).  They concluded that 
both calcium channel blockers attenuated the cardiovascular responses and this effect 
was greatest with verapamil 0.1mg/kg body weight. 
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FUJII et al(1998)51 studied the inhibitory effect of nicardipine 30µg/Kg body 
weight on the hemodynamic effects of tracheal extubation in hypertensive patients and 
compared it  with diltiazem 0.2mg/kg body weight.   They concluded that diltiazem 
when compared to nicardpine produces greater attenuation of circulatory responses to 
tracheal extubation in the hypertensive population.
YUHJI SAITOH & YOSHITAKA FUJI (1999)  44 did a randomized double 
blind study to evaluate the  efficacy of  combination of  diltiazem and lignocaine in 
suppressing  the  hemodynamic  changes  during  tracheal  extubation  in  hypertensive 
patients undergoing elective orthopedic surgery.  They concluded that the combination 
of diltiazem and lignocaine is more effective prophylaxis than diltiazem or lignocaine 
alone  for  attenuating  the  cardiovascular  responses  to  tracheal  extubation  and 
emergence from anaesthesia in hypertensive patients.
MATERIALS AND METHODS
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The  study  was  done  to  compare  the  efficacy  of  combined  diltiazem  and 
lignocaine  with  that  of  giving  each  of  these  drugs  separately  in  suppressing  the 
hemodynamic changes during tracheal extubation in patients posted for elective spine 
surgeries (lumbar & cervical spine). The study comprised of 60 patients of both sex in 
the age group of 16 to 60 years.  All the patients were informed of the study and prior 
written informed consent was obtained.  The surgeon was also informed about the 
study. 
           Patients were assessed by a detailed history & physical examination supported 
by  investigations  like  routine  blood  tests  –  Hb,  blood  sugar,  blood  urea,  serum 
creatinine, serum electrolytes, chest X-ray PA view and Electrocardiogram. 
INCLUSION CRITERIA
1) Patients in ASA Physical Status I & II.
2) Age 16 to 60 years.
3) Patients with modified Mallampatti scores I & II.
EXCLUSION CRITERIA
1) Patients with predicted difficult airway.
2) Patients with co-existing cardio vascular diseases (Hypertension,   conduction 
            blocks , Ischaemic heart diease & cardiac failure).
3) Patients on cardiovascular drugs (β-blockers, Calcium channel blockers).
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4) Patients with heart rate < 60 beats / min. (hypothyroidism, sinus node disease,  
          other medications).
5) Patients with blood pressure less than 100/60mm Hg.
6) Patients with documented hepatic or renal disease.
7) Pregnant patients.
ANAESTHESIA PROTOCOL
Pre-operative visit was done to allay anxiety and a good rapport was established 
with the patient.
PREMEDICATION:
All  the  patients  were  given  Tab-Diazepam  10  mg.  orally  the  night  before 
surgery.   Tab-Ranitidine  150mg and T-Metoclopromide 10mg were given one and 
half-hours before surgery.  All the patients were given Inj.  Atropine 20μg/kg body 
weight intramuscularly 45 minutes before surgery. 
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MONITORING
After  receiving  the  patient  in  the  operating  room the  heart  rate  and arterial 
oxygen saturation of all patients were monitored continuously .  The heart rate was 
monitored  by  electrocardiography (lead  II)  while  the  blood pressure  was  recorded 
using an automated non-invasive blood pressure monitor.  An intravenous cannula was 
inserted after infiltration with local anaesthetic.
INDUCTION AND INTUBATION:
All  patients  were  pre  oxygenated  for  3  min.  and  anaesthesia  induced  with 
intravenous administration of Thiopentone (5mg/kg) and Fentanyl citrate (2µg/Kg). 
Tracheal  intubation  was  facilitated  by  intravenous  administration  of  Vecuronium 
bromide (0.1mg/Kg).  Anaesthesia maintained with Isoflurane (0.5-1%) and Nitrous 
oxide  (66%)  in  O2.  Supplemental  doses  of  Fentanyl  and  Vecuronium  were 
administered when required.
Patients were randomly allocated to one of the three groups before the end of 
surgery. 
Group L - 1.5mg/Kg body weight of Lignocaine + Saline.
Group D - 0.1mg/Kg body weight of Diltiazem  + Saline.
Group D-L - 0.1mg/Kg body weight of Diltiazem + 
1.5mg/Kg body weight of Lignocaine.
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Identical  syringes  containing  each  drug  were  prepared  by  personnel  not 
involved in the study.
The BP (systolic, diastolic and mean) and heart rate before start of skin closure 
were recorded as the baseline values.  At the start of skin closure volatile anaesthetic 
was cut off.  Residual neuromuscular blockade was reversed at the end of surgery with 
neostigmine methyl sulphate (0.05 mg/kg body weight) and atropine sulfate 
(0.02mg/kg body weight) administered intravenously. Once the patient started 
breathing regularly nitrous oxide was discontinued.  The study drug was then 
administered a minimum of 3 minutes after reversing the patient over a period of 60 
seconds. The trachea was extubated a minimum of two minutes after administration of 
study drug.  All patients were administered 100% oxygen by face mask and heart rate, 
blood pressure were recorded every minute for a period of five minutes.  The patients 
were monitored in recovery room for a period of at least 30 minutes.
Ease of tracheal extubation:
The  quality  of  tracheal  extubation  was  evaluated  using  a  three  point  rating 
scale.
1 = no cough or straining.
            2 = minimal coughing.
            3 = high degree of coughing or straining.
            All values were expressed as mean+ SD.  Differences in hemodynamic 
variables were determined by ANOVA.  If  ANOVA detected differences post  hoc 
41
analysis was performed with t-tests to examine intragroup differences.  All post hoc 
comparisons were adjusted appropriately using Bonferroni's correction.  A p value of < 
0.05 was considered significant.    
OBSERVATION AND RESULTS
Sixty patients under this study were categorized into three groups.  20 in each 
group.  They comprised both sexes in the age group 16 to 60 years. The demographic 
profile is as follows:
Characteristics Group – D(Diltiazem)
Group – L
(Lignocaine)
Group D – L
(Diltiazem and 
Lignocaine).
Age (Years) 35.83 + 12.26 35.37 + 11.49 33.63 + 11.50
Sex
M – 11
F – 9
M – 13
F – 7
M – 11
F – 9
Weight (Kgs.) 54.67 + 7.90 55.68 + 8.24 55.32 + 7.89
Duration of 
anaesthesia (min) 110.56 + 22.55 110.00 + 31.22 116.32 + 20.87
Basal heart rate 
(bpm) 80.44 + 8.66 76.74  + 7.12 77.47 + 7.29
Basal systolic 
blood pressure 
(mm Hg)
123.67 + 6.90 121.05 + 8.70 121.58 +  6.91
Basal diastolic 
blood pressure 
(mm Hg)
83.17 + 6.49 81.79 + 7.60 80.21 + 6.03
Total dose of 
fentanyl (μg) 133.06 + 21.15 136.05 +26.85 144.21 + 21.55
Total dose of 
Vecuronium (mg) 9.67 + 1.53 10.11 + 1.97 10.37 + 1.42
Blood loss (ml) 135.55 + 8.07 140.73 +  12.59 137.89 + 10.44
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Age Group (Years)
GROUP N Mean Standard Deviation F-test
D 20 35.83 12.26
L 20 35.37 11.49
D – L 20 33.63 11.50
F = 0.18
P = 0.83
In the Group  D, the mean age was 35.83 + 12.26 years, ranging from 18 years 
to 58 years. In the Group  L the mean age was 35.37 + 11.49 years, the range being 18 
years to 55 years and in the Group D – L, it was 33.63 + 11.50 years, the range being 
18 years  to  53 years.   Thus there was no significant  difference between the three 
groups as their p = 0.83 (p value of significance being < 0.05).
Sex Distribution
Sex Group – D Group – L Group D – L Total
Male 11 13 11 35
Female 9 7 9 25
Total 20 20 20 60
χ2 = 0.55 p = 0.77 (p value of significance being < 0.05).
The sex distribution between the three groups is equal as shown in the bar chart, 
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the difference being insignificant (p = 0.77).
Weight Distribution  (Kgs)
GROUP N Mean (kgs) Standard Deviation F-test
D 20 54.67 7.90
L 20 55.68 8.24
D – L 20 55.32 7.89
F = 0.07
P = 0.93
In the group D, the mean weight was 54.67 + 7.90 Kg ranging from 40 Kg to 65 
Kg. In the Group L, the mean weight was 55.68 + 8.24 Kg, the range being 42 Kg to 
76 Kg and in group D – L the mean weight was 55.32 + 7.89 Kg, the range being 40 
Kg to 72 Kg.  Thus there was no significant difference between the three groups as 
their p value = 0.93.
Baseline Hemodynamic Parameters
There was no statistically significant difference in the baseline hemodynamic 
parameters between the three groups.
Basal Heart Rate (bpm)
GROUP N Mean Standard Deviation F-test
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D 20 80.44 8.66
L 20 76.74 7.12
D – L 20 77.47 7.29
F = 3.03
P = 0.08
Basal Systolic Blood Pressure (mm Hg)
GROUP N Mean Standard Deviation F-test
D 20 123.67 6.90
L 20 121.05 8.70
D – L 20 121.58 6.91
F = 0.61
P = 0.55
Basal Diastolic Blood Pressure (mm Hg)
GROUP N Mean Standard Deviation F-test
D 20 83.17 6.49
L 20 81.79 7.60
D – L 20 80.21 6.03
F = 0.89
P = 0.42
There was also no statistically significant difference for the total dose of opioid 
(fentanyl citrate) or muscle relaxant (Vecuronium) used between the groups.
Total dose of fentanyl (μg).
GROUP N Mean Standard Deviation F-test
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D 20 133.06 21.15
L 20 136.05 26.85
D – L 20 144.21 21.55
F = 1.13
P = 0.33
Total dose of Vecuronium (mg)
GROUP N Mean
Standard 
Deviation
F-test
D 20 9.67 1.53
L 20 10.11 1.97
D – L 20 10.37 1.42
F = 0.84
P = 0.44
Heart Rate (bpm)
GROUP
Base
line
IMIN 
after 
Study 
Drug 
Admn
Tracheal Extubation
Immediate 1 min. 2 min 3 min 5 min
REC 
room
D
83.00 
+ 9.43
98.83
+ 11.55
100.78
+ 15.10
91.67 
+ 14.52
85.67 
+ 13.53
81.72 
+ 11.69
81.17 
+ 10.67
81.56 
+ 10.85
L
83.21 
+ 9.13
92.16 
+ 10.04
99.95 
+ 10.23
90.63 
+ 12.70
84.42
 + 11.07
80.37 
+ 10.17
78.32 
+ 8.30
76.89 
+ 7.19
D – L
87.05 
+ 10.97
89.26 
+ 9.66
87.95 
+ 9.02
81.37 
+ 7.62
79.37 
+ 8.93
78.32 
+ 8.16
77.42 
+ 7.27
77.16 
+ 6.78
The arithmetic mean of the baseline heart rate for the D , L and D-L groups 
were 83.00 + 9.43, 83.21 + 9.13 and  87.05 + 10.97 beats per min respectively. There 
was no statistically significant difference between the mean baseline heart rates for the 
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three groups (p = 0.37).
The heart rate increased in all the three groups after extubation and this increase 
was maximal immediately after extubation.
In the D group the increase in heart rate above the baseline was statistically 
significant 1 min after administration of study drug (p = 0.002) and immediately after 
tracheal extubation (p = 0.000).  Even though the heart rate in the 1st min & 2nd  min 
after tracheal extubation was higher than baseline, this increase was statistically not 
significant (p = 0.51[1st min], p = 1.00 [2nd min]).  The heart rate dipped below the 
baseline value by the third minute and this decrease was statistically not significant in 
the third (p = 1.000) and fifth minute (p=1.000).
In the L group the increase in the heart rate over the baseline was statistically 
significant immediately after tracheal extubation (p = 0.000). The heart rate remained 
over the baseline till 2 min after tracheal extubation.  The heart rate dipped below the 
baseline  from  the  third  min  after  tracheal  extubation.  This  decrease  was  not 
statistically significant. 
In the D-L group the heart rate increased above the baseline immediately after 
tracheal extubation.  This increase was not statistically significant (p = 1.000).  The 
heart  rate dipped below the baseline by the first  minute but this  decrease was not 
statistically  significant.  The decrease  in  the  heart  rate  in  the  second,  third  & fifth 
minute after tracheal extubation was also not statistically significant (p=1.000).
47
The mean heart rates of the D,L & D-L groups in the recovery room were 81.56 
+ 10.85, 76.89 + 7.19 and 77.16 + 6.78 beats per minute respectively which were not 
statistically significant (p = 0.180).
Systolic Blood Pressure (mm Hg)
GROUP
Base 
line
IMIN 
after 
Study 
Drug 
Admn.
Tracheal Extubation
Immediate 1 min. 2 min 3 min 5 min
REC 
room
D
123.06 
+ 11.09
131.61
+ 10.66
132.28
 + 10.91
122.67 
+   11.85
118.22 
+ 10.00
118.61 
+ 8.35
118.94 
+ 8.38
118.72 
+ 7.95
L
120.00 
+ 9.84
128.68 
 + 8.71
134.74
 + 8.90
126.53 
+ 11.99
120.21
 + 11.03
119.21 
+ 9.44
119.05 
+ 9.63
119.32
 + 8.62
D – L
120.00 
+ 6.64
123.58 
 + 8.25
124.89 
+ 7.41
117.95 
+ 9.11
116.42 
+ 6.56
117.79 
+ 6.79
118.32 
+ 6.93
118.11 
+ 6.26
The mean baseline systolic blood pressure for the D, L and D-L groups were 
123.06 + 11.09, 120.00 + 9.84 and 120.00 + 6.64 mm Hg respectively. There was no 
statistically significant difference (p = 0.52) between the mean baseline systolic blood 
pressure of the three groups.
It  is  apparent from the table that systolic blood pressure increased in all  the 
three groups after extubation and this increase was maximal immediately after tracheal 
extubation.
The  increase  in  systolic  blood  pressure  from  the  baseline  value  was  not 
significant  in  the  D group in  the  first  5  min after  extubation.   The systolic  blood 
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pressure decreased to less than the baseline value in the D group by the second minute, 
but this decrease was not statistically significant (P= 1.000).
In the L group, the increase in the systolic blood pressure over the baseline 
value was significant immediately after tracheal extubation (p=0.000).  The systolic 
blood pressure touched the baseline in the second minute after extubation.  The SBP 
decrease  below the  baseline by the  third minute after  extubation,  but this  was not 
statistically significant (P = 1.000).
In the D – L group, the systolic blood pressure increased above the baseline 
immediately  after  tracheal  extubation  which  was  not  statistically  significant  (p  = 
1.000).  The systolic blood pressure dipped below the baseline value from the first 
minute after tracheal extubation which was also not statistically significant (p = 1.000).
The mean systolic blood pressures in the recovery room were 118.72  + 7.95, 
119.32 + 8.62 and 118.11.  + 6.26 mm Hg for the D, L & D - L groups respectively 
which were statistically not significant (P=0.889).
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Diastolic Blood Pressure (mm Hg)
GROUP Baseline
IMIN 
after 
Study 
drug 
Admn.
Tracheal Extubation
Immediate 1 min. 2 min 3 min 5 min REC room
D
84.94
+ 10.38
87.50
+ 10.39
86.56
+ 11.58
79.67
+   10.49
80.94 
+ 10.45
82.72
+ 11.89
81.78
+ 12.01
82.06
+ 11.47
L
79.21
 + 9.11
86.89 
+ 8.39
90.26 
+ 8.39
82.84 
+ 9.72
81.84 
+ 9.72
78.95 
+ 10.65
77.11 
+ 9.51
77.11
+ 10.00
D – L
82.11
+ 9.07
83.89 
+ 7.10
83.79 
+ 6.99
78.00 
+ 10.89
76.26 
+ 8.04
79.05 
+ 5.64
77.00 
+ 6.64
76.68 
+ 4.92
The arithmetic mean of the baseline diastolic blood pressures for the D, L & D-
L groups were 84.94 + 10.38, 79.21 + 9.11, 82.11 + 9.07 mm Hg. respectively.  There 
was no statistically significant difference between the three groups (p = 0.19).
In the D group, the diastolic blood pressure increased immediately after tracheal 
extubation  which  was  not  statistically  significant  (p=1.000).   The  diastolic  blood 
pressure  decreased  below  the  baseline  value  from  the  first  minute  after  tracheal 
extubation.
In the L group, there was an increase in the diastolic blood pressure from the 
baseline value immediately and in the first two minutes after tracheal extubation.  This 
increase was statistically significant (p = 0.012) immediately after tracheal extubation. 
The diastolic blood pressure decreased below the baseline value by the third minute 
after extubation and continued to do so for the remaining period of study.  
50
In  the  D-L group the  diastolic  blood pressure  decreased below the  baseline 
value from the first minute after extubation and continued to be below the baseline for 
the remainder of the study.  This decrease was statistically not significant.  
The arithmetic  mean of the diastolic  blood pressures of  the D,  L & D – L 
groups in the recovery room were 82.06 + 11.47, 77.11 + 10.00 and 76.68 + 4.92 mm 
Hg respectively.   There  was  no  significant  difference  between the  diastolic  blood 
pressures in the three groups in the recovery room (p = 0.154).
SMOOTHNESS OF EXTUBATION
7 patients out of twenty in the D group (35%) and 1 patient out of twenty (5%) 
in  the  L  group & D –  L  group  had  a  grade  3  extubation  response  –  significant 
coughing and straining. 
11 patients in the D group (55%), 14 patients in the L group (70%) and 13 
patients  in  the   D–  L  group  (65%)  had  grade  2  extubation  response   -  minimal 
coughing .
           2 patients in the D group (10%), 5 patients in the L group (25%) and 6 patients  
in  the  D-L group (30%) had  grade 1 extubation  response  –  no  coughing (smooth 
extubation).
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DISCUSSION
Hypertension and tachycardia usually accompany laryngoscopy and tracheal 
intubation.  Similar hemodynamic changes can occur during emergence from 
anaesthesia and tracheal extubation.  Even though these responses are brief and well 
tolerated by the majority of patients they can be detrimental and cause significant 
clinical problems in susceptible patients.  This is especially so in patients with 
ischemic heart disease, neurosurgical patients and hypertensive patients who 
demonstrate an exaggerated response to tracheal extubation which could prove 
detrimental in the outcome.
Studies  have  shown  the  importance  of  maintaining  stable  hemodynamic 
parameters intraoperatively in high-risk patients.  In the study by Slogoff and Keats in 
patients undergoing coronary artery bypass surgery, they were able to demonstrate that 
the  incidence  of  perioperative  myocardial  ischemia  was  related  to  the  number  of 
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episodes of intraoperative tachycardia34. Asiddao et al studied the factors associated 
with  perioperative  complications  -  neurological  deficits,  myocardial  infraction  and 
mortality in patients undergoing carotid endarterectomy35.   They found out that the 
perioperative  factors  that  unfavorably  affected  the  neurological  outcome following 
carotid  endarterectomy  included  poor  perioperative  blood  pressure  control.   They 
concluded that strict regulation of blood pressure not only during the surgical period 
but also before and after surgery is extremely important in these high-risk patients.
Various pharmacological methods have been used to attenuate the circulatory 
responses  to  tracheal  extubation.  These  include  use  of  intravenous  lignocaine6, 
fentanyl9, alfentanil, esmolol8 and labetolol.
Many studies have reported a beneficial effect of calcium channel blockers in 
attenuating the cardiovascular changes during tracheal extubation and emergence from 
anaesthesia.  Milkawa and Nishina35 demonstrated that both verapamil and diltiazem 
attenuated  the  increases  in  heart  rate  and  arterial  blood  pressure  during  and  after 
tracheal extubation and the inhibitory effect was greatest with verapamil 0.1mg/kg.
Fuji and Kihara36 compared the inhibitory effects of calcium channel blockers, 
nicardipine  and  diltiazem  on  hemodynamic  changes  after  tracheal  extubation  in 
hypertensive  patients.   They  concluded  that  administration  of  diltiazem  produced 
greater attenuation of the circulatory responses to tracheal extubation than nicardipine.
Nishina  and  Mikawa37 in  their  study  compared  the  effects  of  intravenous 
53
diltiazem and lignocaine on hemodynamic changes during tracheal extubation. They 
concluded that a bolus dose of intravenous diltiazem 0.1 or 0.2 mg/Kg given 2 minutes 
before extubation attenuated the cardiovascular changes occurring in association with 
tracheal  extubation.  This  effect  of  diltiazem  was  equal  or  superior  to  that  of 
intravenous lignocaine.
As reported by Nishina and Mikawa a combination of lignocaine and diltiazem 
would  attenuate  hemodynamic  changes  to  more  tolerable  levels  than  each  drug 
administered  alone  because  the  mechanisms  whereby  these  two  drugs  attenuate 
tachycardia  and  hypertension  are  thought  to  be  different.   Hence  this  study  was 
designed to compare the efficacy of combination of diltiazem and lignocaine with each 
drug alone in attenuating the hemodynamic changes during tracheal extubation. 
The rationale for the use of diltiazem at dose of 0.1mg/kg was based on the 
following findings -
(i) Diltiazem 0.1 – 0.2 mg/Kg has been used to treat supraventricular tachycardic 
arrhytmia 38,39 or unstable angina40
(ii) Intravenous diltiazem at doses of 0.09 – 0.23 mg/kg has been used to reduce 
abrupt circulatory changes in response to various surgical stimuli.
(iii) Indian patients require a lower dose of intravenous diltiazem as compared to 
western counterparts  (0.1 mg/kg versus 0.25-0.33 mg/kg) which gives a prompt & 
effective response in patients with supraventricular tachyarrhythmias42 Mikawa et al 
reported one episode of profound hypotension (SBP = 71 mmHg) when diltiazem was 
used  in  a  dose  of  0.3  mg/kg  for  attenuating  hemodynamic  responses  to  tracheal 
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extubation. 
The onset and duration of action of diltiazem are rapid and short.  The MAP 
begins to decrease 20-40 sec after administration of intravenous diltiazem with a peak 
effect occurring at 1.5-2min43.  Lignocaine in a dose of 1-2 mg/kg body weight has 
been used to blunt the pressor response to intubation.  It has been recommended to be 
given 90 sec prior to intubation.  Fujii et al confirmed that MAP begins to increase 
immediately after tracheal extubation and reaches a maximum value within one minute 
when no medication is provided23. Thus the timing of administration of the study drug 
(two minutes before tracheal extubation) was chosen in this study. 
Intravenous administration of the mixture of neostigmine and atropine increases 
heart rate within 1 minute, the effect peaking 1-2min after injection.  The heart rate 
returns to basal values 3 minutes after injection and decreases further until 6 min after 
dosing (44).  In my study the intravenous administration of study drug was after 3 
minutes of injection of neostigmine-atropine mixture and the extubation response was 
analyzed up to five minutes. Hence the early increase in heart rate induced by atropine 
was likely to be excluded. 
HEART RATE CHANGES:
In Group D, the increase in mean heart rate recorded immediately after tracheal 
extubation  was  statistically  significant  from  the  baseline  value  showing  that  the 
attenuation  of  stress  response  by  diltiazem to  extubation  was  not  adequate.   This 
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finding was in concurrence with the study done by Fujii et al. 
In Group L, there was a statistically significant increase in the mean heart rate 
from the baseline to that recorded immediately after tracheal extubation.  This showed 
that there was inadequate attenuation of stress response by lignocaine in Group L. 
This finding was in concurrence with the study done by Fujii et al. 
Patients in Group D-L who received both diltiazem and lignocaine,eventhough 
showed  a  slight  increase  in  heart  rate  from  the  baseline  it  was  not  statistically 
significant.  The increased heart rate recorded is also the least among the groups.  This 
finding was also in concurrence with the study made by Fujii et al.  
Since the increase in mean heart rate was the least in Group D-L, it  can be 
concluded that  the  attenuation of  the  stress  response to  tracheal  extubation is  best 
achieved by a combination of diltazem 0.1mg/kg and lignocaine 1.5mg/kg given 2 
minutes before extubation.  
SYSTOLIC BLOOD PRESSURE (SBP) CHANGES:
In-group D where diltiazem was given 2 minutes before tracheal extubation the 
increase in mean SBP immediately after tracheal extubation (132.28  + 10.91mmHg) 
was not statistically significant from baseline value.  This showed that the pressor 
response to tracheal extubation was adequately attenuated in this group. 
In group L where lignocaine was given, the cardiovascular response to tracheal 
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extubation was not attenuated as shown by the statistically significant increase in the 
mean  SBP  values  (134.74  + 8.90mmHg)  recorded  immediately  after  tracheal 
extubation from the baseline value.  This finding was in concurrence with the study 
done by Fujii et al. 
In Group D-L, the increase in mean SBP immediately after tracheal extubation 
was the least among the four groups (124.89 + 7.41 mmHg).  This increase was not 
statistically significant proving that the pressor response to tracheal extubation was 
adequately obtunded by combination of diltiazem and lignocaine.
From  the  above  finding  both  Group  D  and  Group  D-L  showed  adequate 
attenuation of pressor response to tracheal extubation.  Since the increase in mean SBP 
immediately after tracheal extubation was the least in Group D-L, it can be concluded 
that the pressor response to tracheal extubation is best attenuated when both diltiazem 
(0.1mg/Kg)  and lignocaine  (1.5mg/kg)  are  given  in  combination  2  minutes  before 
tracheal extubation. 
DIASTOLIC BLOOD PRESSURE (DBP) CHANGES:
In Group D, the increase in mean DBP following tracheal extubation was not 
statistically  significant  from  the  baseline  value.   Patients  in  Group  L  showed 
significant  increase  in  DBP following tracheal  extubation.   Patients  in  Group D-L 
showed the maximum attenuation of DBP changes which follow tracheal extubation.
57
SMOOTHNESS OF EXTUBATION
The diltiazem group had significantly greater episodes of severe coughing or 
straining (grade 3).  The diltiazem group also had fewer smooth extubation (grade 1) 
as compared to the other two groups.  Intravenous lignocaine is known to suppress the 
cough reflex in both awake and anaesthetized patients.  The exact mechanism of action 
of the antitussive effect of intravenous lignocaine is not known but could be either due 
to local anaesthetic effect in the pharynx or due to an action in the central nervous 
system.
Steinhaus  et  al  studied  the  effectiveness  of  intravenous  lignocaine  in 
suppressing  the  cough  reflex  of  anaesthetized  patients  who  were  intubated  but 
spontaneously breathing45.  Lignocaine prevented cough in  eight  of  the  ten patients 
stimulated by manual displacement of the endotracheal tube.  Poulton et al studied the 
ability of intravenous lignocaine in awake individuals in whom coughing was induced 
by citiric acid aerosol inhalation to suppress the cough reflex46. They found out that 
intravenous lignocaine had a significant effect in decreasing the cough responses of 
awake unmedicated subjects.   Yukioka et al studied the dose and plasma levels of 
lignocaine required to suppress coughing during tracheal intubation.  They concluded 
that coughing was eliminated with plasma concentrations of lignocaine in excess of 
3µg/ml.   Because  of  its  antitussive  effect  lignocaine  was  commonly  used  during 
recovery from anaesthesia for neurosurgical and certain ophthalmologic procedures.
Episodes of perioperative hypertension and tachycardia with its consequent ill 
58
effects  on  the  vital  organs  can  be  a  significant  problem in  some  patients  despite 
adequate depth of anaesthesia and analgesia.  Bolus intravenous doses of  β-blockers 
are usually used in such situations.  In case of co-existing reactive airway disease one 
would  hesitate  to  administer  β-blockers.   This  study  shows  that  bolus  doses  of 
diltiazem and lignocaine can be safely administered in such situations leading onto 
normalization of hypertension and tachycardia. 
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SUMMARY
This prospective randomized study was designed to evaluate the efficacy of 
combination  of  diltiazem and lignocaine  in  suppressing  the  hemodynamic  changes 
during  tracheal  extubation.  The  effect  of  Diltiazem-Lignocaine  combination  was 
compared with that of Diltiazem and Lignocaine given individually.
           A total of sixty patients belonging to ASA physical status 1 and 2 were 
randomly divided into three groups. Patients in Group D received Inj.Diltiazem 0.1mg/
kg, patients in Group L received Inj.Lignocaine 1.5mg/kg and patients in Group D-L 
received  both  Inj.Diltiazem  0.1mg/kg  and  Inj.Lignocaine  1.5mg/kg.  Tracheal 
extubation was done two minutes after administration of study drug. Changes in heart 
rate and blood pressure were measured up to five minutes after tracheal extubation.
         The following observations were made
 Patients in Group D-L showed the maximum attenuation of heart rate and 
blood pressure changes following tracheal extubation..
 Patients in Group D showed a significant increase in heart rate (p < 0.05) 
after extubation but the increase in blood pressure was not significant.
 Patients in Group L showed significant increase in both heart rate and blood 
pressure following tracheal extubation.
 The  percentage  of  patients  who  had  significant  coughing  and  straining 
during extubation was   greater in Group D than in the other two groups. 
 No patients in any of the three groups developed laryngeal spasm, profound 
hypotension(SBP < 80mmHg) or bradycardia (HR < 50 bpm). 
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                               CONCLUSION
         From the above study it is concluded that the hemodynamic changes associated 
with extubation of  trachea can be  effectively obtunded by using a  combination of 
Diltiazem and Lignocaine than giving each drug separately.
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ATTENUATION OF HEMODYNAMIC RESPONSES TO TRACHEAL 
EXTUBATION : COMPARISON OF DILTIAZEM, LIGNOCAINE AND 
DILTIAZEM-LIGNOCAINE COMBINATION.
NAME: AGE/SEX :
IP NO   :                                                               UNIT        :
DIAGNOSIS:                                                       ANAESTHESIOLOGIST:
NAME OF THE OPERATION :
HISTORY IN BRIEF :
Previous anaesthetic experience :
Drug allergy :
Others  :
GENERAL EXAMINATION :
Weight :
Oedema / pallor / icterus / clubbing / lymphadenopathy
PR : 
BP : 
SYSTEMIC EXAMINATION :
CVS : 
RS : 
CNS :
AIRWAY :
INVESTIGATIONS : 
Hb :                      
RBS/FBS :        
Blood urea :
Serum creatinine :
Chest X-Ray :
ECG : 
INCLUSION CRITERIA :
          -ASA 1 & ASA 2 patients between ages of 16 and 60 years. 
EXCLUSION CRITERIA :
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          -Patients with coexisting cardiovascular diseases or on cardiovascular drugs
          -Patients with heart rate less than 60 beats/min
          -Patients with blood pressure less than 100/60 mmHg
          -Patients with documented hepatic or renal disease.
PREMEDICATION :          
   Tab Diazepam 10 mg PO ; HS night before surgery.
   Tab Ranitidine 150 mg PO ; 6AM on day of surgery. 
Inj.Atropine– 20μg/kg  im 45 min before surgery
PREOXYGENATION :
 With 100% oxygen for 3 min.    
INDUCTION OF ANAESTHESIA : 
         Anaesthesia induced with Inj.Thiopentone 5mg/kg and Inj.Fentanyl citrate 2μg/kg . 
Tracheal intubation was facilitated by intravenous administration of Vecuronium 0.1mg/kg. 
Anaesthesia  maintained  with  Isoflurane(0.5-1%)  and  Nitrous  oxide(66%)  in  O2. 
Supplemental doses of Fentanyl and Vecuronium were administered as required.  
          Patients were randomly allocated to one of the three groups before the end of surgery.
GROUP D : 0.1mg/kg body weight of Diltiazem  plus Saline.
GROUP L : 1.5 mg/kg body weight of Lignocaine plus Saline.
GROUP D-L : 0.1 mg/kg Diltiazem plus 1.5 mg/kg of Lignocaine.
         These medications were given a minimum of 3min after reversing the patient with 
Inj.Neostigmine (0.05 mg/kg) & Inj.Atropine(0.02mg/kg). Trachea was extubated a minimum 
of 2 min after administration of study drug.
Total dose of Fentanyl(μg) :
Total dose of Vecuronium(mg) :
Blood loss :
SYSTOLIC BP
(mmHg)
DIASTOLIC BP
(mmHg)
HEART RATE
(bpm)
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Baseline value
Administration of study 
drug
1min after admn of study 
drug
Tracheal extubation
Post extubation(1min)
Post extubation(2min)
Post extubation(3min)
Post extubation(5min)
Smoothness of extubation :
          Grade 1 : No coughing
          Grade 2 : Minimal coughing
          Grade 3 : Significant coughing/straining. 
Recovery room HR :                                          BP :  
Complications if any :
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